Teva Pharmaceutical Industries Aktie

15,05 EUR +0,15 EUR +1,01 %

11:10:40

STU

16,46 USD -0,02 USD -0,12 %

13.03.2025

BTT

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

Div. Rendite0,00%

WKN883035

ISINUS8816242098

SymbolTEVA

Teva Pharmaceutical Industries Aktien News

Sortieren:Datum Meistgelesen

08:27PR NewswireTeva Upgrades Its 4PL Model, Enhancing Medicine Accessibility for Patients with Kerry Pharma

03.03.25GlobeNewswireTeva to Present at Barclays Global Healthcare Conference and Leerink Partners Global Healthcare Conferences in March

27.02.25GlobeNewswire2025 Community Routes: Access to Mental Health Care Grants Awarded to Clinics in Alabama, Mississippi, and Texas, Funded by Teva Pharmaceuticals

WerbungTeva Pharmaceutical Industries-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

25.02.25GlobeNewswireTeva and Medincell Announce FDA Acceptance of Supplemental New Drug Application for UZEDY(R) (risperidone) Extended-Release Injectable Suspension as a Treatment for Patients with Bipolar I Disorder

22.02.25GlobeNewswireTeva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn’s Disease

21.02.25GlobeNewswireDer Patient steht an erster Stelle: Warum Europa handeln muss, um den Zugang zu Arzneimitteln zu sichern

21.02.25GlobeNewswireTeva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.

18.02.25GlobeNewswireTeva to Host Conference Call on February 24, 2025 to Discuss New Data Presented for Duvakitug (anti-TL1A) Positive Phase 2b results at the 20th Annual Congress of the European Crohn's and Colitis Orga

18.02.25GlobeNewswireAlvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)

27.01.25GlobeNewswireAlvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab)

14.01.25GlobeNewswireTeva gibt Zusammenarbeit zur Vermarktung des Formycon Biosimilar-Kandidaten für Eylea® (Aflibercept) in großen Teilen Europas und in Israel bekannt

13.01.25GlobeNewswireTeva Announces Collaboration to Commercialize Formycon’s Biosimilar Candidate to Eylea® (aflibercept) in major parts of Europe and in Israel

10.01.25GlobeNewswireSamsung Bioepis and Teva Enter into a Strategic Partnership for Commercialization of EPYSQLI® (eculizumab-aagh) in the United States

23.12.24GlobeNewswireTeva to Present at the 43rd Annual J.P. Morgan Healthcare Conference

20.12.24GlobeNewswireTeva to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and 2025 Financial Guidance at 8 a.m. ET on January 29, 2025

17.12.24GlobeNewswireTeva and Sanofi Announce Duvakitug (Anti-TL1A) Positive Phase 2b Results Demonstrating Best-in-Class Potential in Ulcerative Colitis and Crohn’s Disease

11.12.24GlobeNewswireTeva Announces New Patient Access Program with Direct Relief to Provide Access to Inhalers for Uninsured Patients

06.12.24GlobeNewswireTeva Announces Agreement to Divest Teva-Takeda, its Business Venture in Japan

04.12.24GlobeNewswireTeva präsentiert positive Wirksamkeits- und Sicherheitsdaten von AJOVY® (Fremanezumab) zur Vorbeugung episodischer Migräne bei Kindern und Jugendlichen aus der Phase-III-Studie SPACE

04.12.24GlobeNewswireTeva Presents Positive Efficacy and Safety Data of AJOVY® (fremanezumab) for the Prevention of Episodic Migraine in Children and Adolescents from Phase 3 SPACE Trial

26.11.24GlobeNewswireTeva to Present at the 7th Annual Evercore ISI HealthCONx Conference

08.11.24GlobeNewswireTeva to Present at the Jefferies London Healthcare Conference

01.11.24GlobeNewswireTeva Presents New Tardive Dyskinesia Data at Psych Congress 2024 from the IMPACT-TD Registry, Revealing Differences in Patient Experience Based on Underlying Psychiatric Condition

01.11.24GlobeNewswireTeva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrating Improvements in Social Functioning and Quality of Life in Adults Receiving TEV-'749 (olanza

31.10.24GlobeNewswireTeva Statement on European Commission Decision; Company to Appeal

22.10.24GlobeNewswireAlvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (us

08.10.24GlobeNewswireTeva Prolia® (Denosumab) Biosimilar Candidate is Accepted for Review by U.S. FDA and EU EMA

03.10.24GlobeNewswireTeva and mAbxience Expand Strategic Partnership to include an additional Oncology Biosimilar Candidate

01.10.24GlobeNewswireTeva Announces Launch of the First and Only Generic Version of Sandostatin® LAR Depot (octreotide acetate for injectable suspension), in the U.S.

30.09.24GlobeNewswireTeva to Host Conference Call to Discuss Third Quarter 2024 Financial Results at 8 a.m. ET on November 6, 2024

23.09.24GlobeNewswireTeva Announces Long Term Efficacy and Safety of Deutetrabenazine in European Patients with Debilitating Movement Disorder Tardive Dyskinesia

21.09.24GlobeNewswireTeva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable for Adult Patients Diagnosed

21.09.24GlobeNewswireNew Data Provide Treatment Insights into Options for Switching Adult Patients Diagnosed with Schizophrenia to UZEDY® (risperidone) Extended-Release Injectable Suspension from Perseris® (RBP-7000)

11.09.24GlobeNewswireTeva to Present at the Bank of America 2024 Global Healthcare Conference

26.08.24GlobeNewswireTeva to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

14.07.22PR NewswireTeva Pharmaceuticals erhält Siegel als „Migränefreundlicher Arbeitsplatz"

13.07.22PR NewswireTeva Pharmaceuticals accredited Migraine Friendly Workplace Stamp

05.04.22PR NewswireTeva Canada Charts a New Prescription for Care

Teva Pharmaceutical Industries News

Teva Pharmaceutical Industries News: auf dieser Seite finden Sie alle Teva Pharmaceutical Industries News und Nachrichten zur Teva Pharmaceutical Industries Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Teva Pharmaceutical Industries News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Teva Pharmaceutical Industries News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.